远大控股: 关于收到业绩承诺补偿款的公告

Group 1 - The company plans to acquire 85.1166% equity of Fujian Kaili Biological Products Co., Ltd. for a cash consideration of 478,945,645.47 yuan [1] - The acquisition was approved during the fifth meeting of the ninth board of directors and subsequently ratified in a temporary shareholders' meeting [1] - The performance commitment period for Kaili Biological is set for the years 2021, 2022, and 2023, with a total net profit commitment of no less than 12,600 million yuan [2] Group 2 - Kaili Biological achieved a cumulative net profit of 12,352.89 million yuan from 2021 to 2023, falling short of the committed net profit [3] - As a result of the shortfall, the performance commitment parties are required to compensate the company with a cash amount of 9,393,036.39 yuan [3] - The received compensation will positively impact the company's operating performance for the year 2025, increasing the net profit attributable to shareholders by the same amount [3]